Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligand therapy platform addressing multiple aggressive solid tumors, hereby publishes the Year-end report Q4 2025. The Year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.
Curasight's CEO Ulrich Krasilnikoff comments:
"Q4 2025 marked strong momentum, as we advanced the company to become a clinical-stage therapeutic company pioneering uTREAT® - our first-in-class RLT platform targeting uPAR across multiple tumor types. uTREAT® is supported by uTRACE®, our clinically validated uPAR PET diagnostic platform built on the same ligand. uTRACE® enables a true theranostic approach by supporting patient selection, confirming tumor targeting, and de-risking therapeutic development through human imaging validation. We dosed the first patient in our Phase 1 uTREAT® trial in glioblastoma, advancing the program into active clinical development and remaining on track to report top-line data in 2026. uTRACE® continued to progress in the Phase 2 prostate cancer trial and is also on track for top-line data in 2026. With a strengthened balance sheet following DKK 63.4 million in cash and DKK 40 million in new and renegotiated debt facilities, we enter 2026 focused on disciplined execution and delivery of key clinical milestones."
Q4 (2025-10-01 - 2025-12-31)
- Gross loss amounted to kDKK -14,577 (kDKK -10,210)
- Operating loss amounted to kDKK -16,203 (kDKK -11,924)
- Loss before tax amounted to kDKK -16,686 (kDKK -12,334)
- Loss for the period amounted to kDKK -15,311 (kDKK -10,959)
- Total assets amounted to kDKK 50,055 (kDKK 23,688)
- Equity ratio amounted to 37.1% (32.6%)
- Earnings per share amounted to DKK -0.32 (DKK -0.58)
Q1-Q4 (2025-01-01 - 2025-12-31)
- Gross loss amounted to kDKK -49,676 (kDKK -32,731)
- Operating loss amounted to kDKK -55,592 (kDKK -40,367)
- Loss before tax amounted to kDKK -58,730 (kDKK -42,336)
- Loss for the year amounted to kDKK -53,230 (kDKK -36,836)
- Total assets amounted to kDKK 50,055 (kDKK 23,688)
- Equity ratio amounted to 37.1% (32.6%)
- Earnings per share amounted to DKK -1.1 (DKK -1.74)
Numbers in parenthesis are the numbers from the same period in 2024.